Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford OX3 7HE, UK.
Regen Med. 2013 Sep;8(5):613-30. doi: 10.2217/rme.13.55.
Mesenchymal stem cells (MSCs) have become an area of intense interest in the treatment of musculoskeletal conditions, such as muscle and tendon injury, as various animal and human trials have demonstrated that implantation with MSCs leads to improved healing and function. However, these trials have usually been relatively small scale and lacking in adequate controls. Additionally, the optimum source of these cells has yet to be determined, partly due to a lack of understanding as to how MSCs produce their beneficial effects when implanted. Scaffolds have been shown to improve tissue-engineering repairs but require further work to optimize their interactions with both native tissue and implanted MSCs. Robust, well-controlled trials are therefore required to determine the usefulness of MSCs in musculoskeletal tissue repair.
间充质干细胞（MSCs）在肌肉骨骼疾病的治疗中成为一个研究热点，如肌肉和肌腱损伤，因为各种动物和人体试验表明，MSC 的植入导致愈合和功能的改善。然而，这些试验通常规模较小，缺乏足够的对照。此外，这些细胞的最佳来源尚未确定，部分原因是由于缺乏了解 MSC 植入时如何产生其有益效果。支架已被证明可以改善组织工程修复，但需要进一步的工作来优化它们与天然组织和植入的 MSC 的相互作用。因此，需要进行强有力的、对照良好的试验来确定 MSC 在肌肉骨骼组织修复中的有用性。
